BIIB

Biogen
D

BIIB

Arincen57/100B
251.575
USD
1.06
(0.42%)
Market Open
Last updated: · Delayed 15 min
Fair value393.61Plus-36%295Price 251.58492
Q4 FY2026 · Earnings report
EPS estimate 2.81Revenue estimate 2.61B
OverviewFinancialsForecastEarningsCompany

Biogen revenue 1985–2026

Biogen's revenue in Q3 FY2026, the three months to 30 September 2026, was 2.80B USD, up 10.6% on the same quarter a year before. Biogen's revenue over the last twelve months was 10.30B USD, up 2.3% on the twelve months before. In fiscal year 2025 it was 9.89B USD, up 2.2% on the year before.

Last updated 9 Nov 2026 · Next report 5 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202610.30B+2.30%7.21B347.50M
FY202531 Dec 20259.89B+2.22%6.91B1.29B
FY202431 Dec 20249.68B-1.62%7.37B1.63B
FY202331 Dec 20239.84B-3.32%7.30B1.16B
FY202231 Dec 202210.17B-7.36%7.90B3.05B
FY202131 Dec 202110.98B-18.32%8.87B1.56B
FY202031 Dec 202013.44B-6.49%11.64B4.00B
FY201931 Dec 201914.38B+6.88%12.42B5.89B
FY201831 Dec 201813.45B+9.61%11.64B4.43B
FY201731 Dec 201712.27B+7.21%10.64B2.54B
FY201631 Dec 201611.45B+6.36%10.02B3.70B
FY201531 Dec 201510.76B+10.93%9.52B3.55B
FY201431 Dec 20149.70B+39.97%8.53B2.93B
FY201331 Dec 20136.93B+25.70%6.07B1.86B
FY201231 Dec 20125.51B+9.23%4.97B1.38B
FY201131 Dec 20115.05B+7.04%4.58B1.23B
FY201031 Dec 20104.72B+7.75%4.32B1.01B
FY200931 Dec 20094.38B+6.83%4.00B970.13M
FY200831 Dec 20084.10B+29.19%3.70B783.17M
FY200731 Dec 20073.17B+18.21%2.84B638.17M
FY200631 Dec 20062.68B+56.57%2.41B217.51M
FY200531 Dec 20051.71B+7.38%1.34B160.71M
FY200431 Dec 20041.60B+757.35%1.04B25.09M
FY200331 Dec 2003186.13M-53.95%-98.61M-875.10M
FY200231 Dec 2002404.22M-61.22%402.77M148.09M
FY200131 Dec 20011.04B+12.60%905.80M272.68M
FY200031 Dec 2000925.67M+16.52%800.47M333.58M
FY199931 Dec 1999794.44M+42.48%683.43M220.45M
FY199831 Dec 1998557.59M+28.46%483.08M138.70M
FY199731 Dec 1997434.04M+56.64%383.86M89.17M
FY199631 Dec 1996277.09M+82.67%248.57M40.53M
FY199531 Dec 1995151.69M-2.98%141.19M5.66M
FY199431 Dec 1994156.34M+14.62%146.40M-4.90M
FY199331 Dec 1993136.40M+10.27%130.90M32.40M
FY199231 Dec 1992123.70M+101.47%121.50M38.30M
FY199131 Dec 199161.40M+22.55%18.10M7.20M
FY199031 Dec 199050.10M+75.79%14.70M7.70M
FY198931 Dec 198928.50M+38.35%3.30M3.20M
FY198831 Dec 198820.60M+139.53%-500.00K-1.20M
FY198731 Dec 19878.60M+34.38%-12.40M-22.60M
FY198631 Dec 19866.40M-57.62%-16.90M-28.20M
FY198531 Dec 198515.10M—10.60M-19.10M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Biogen revenue growth by segment

Q3 FY2026 against Q3 FY2025

MS Product Revenues919.30M
-13.4%
SPINRAZA460.60M
+23.2%
TYSABRI product437.10M
+1.2%
Fumarate274.00M
-28.4%
Interferon208.20M
-15.7%

Biogen revenue by segment over time

MS Product Revenues TYSABRI product SPINRAZA Fumarate Interferon
Fiscal yearMS Product RevenuesTYSABRI productSPINRAZAFumarateInterferon
FY20254.04B -7.1%1.67B -2.9%1.55B -1.7%1.43B -10.6%945.60M -2.3%
FY20244.35B -6.7%1.72B -8.6%1.57B -9.6%1.60B +0.4%968.00M -12.5%
FY20234.66B -14.1%1.88B -7.6%1.74B -2.9%1.59B -20.5%1.11B -15.3%
FY20225.43B -10.9%2.03B -1.6%1.79B -5.9%2.00B -15.5%1.31B -16.6%
FY20216.10B -22.2%2.06B +6.0%1.91B -7.2%2.36B -39.5%1.57B -16.6%
FY20207.83B -8.2%1.95B +2.8%2.05B -2.1%3.91B 1.88B -10.7%
FY20198.53B -0.8%1.89B +1.5%2.10B +21.6%— 2.10B -11.1%
FY20188.60B 1.86B -5.5%1.72B +95.1%— 2.36B
FY2017— 1.97B +0.5%883.70M +19,110.9%— —
FY2016— 1.96B +4.1%4.60M — —

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Biogen's revenue

Source: Financial Modeling Prep